Zoledronic acid sequential therapy could avoid disadvantages due to the discontinuation of less than 3-year denosumab treatment
Hideomi Kondo, Nobukazu Okimoto, Toru Yoshioka, Shojiro Akahoshi, Yoshifumi Fuse, Takayuki Ogawa, Yuichi Okazaki, Yuji Katae, Manabu Tsukamoto, Yoshiaki Yamanaka, Makoto Kawasaki, Akinori Sakai
Topics & Concepts
DiscontinuationDenosumabMedicineZoledronic acidOsteoporosisBone mineralIncidence (geometry)UrologyInternal medicineOpticsPhysicsBone health and osteoporosis researchBone health and treatmentsManagement of metastatic bone disease